See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Novartis AG (NVS) - free report >>
Bristol Myers Squibb Company (BMY) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis AG (NVS) - free report >>
Bristol Myers Squibb Company (BMY) - free report >>
Image: Bigstock
PDL BioPharma Agrees to Equity Investment in Noden Pharma
PDL BioPharma, Inc. (PDLI - Free Report) announced that it has committed to an equity investment in privately held Noden Pharma DAC in a bid to acquire global rights to manufacture, market and sell Tekturna and Tekturna HCT.
Under the terms of the agreement, PDL BioPharma will pay equity contributions of approximately $107 million to Noden in the first year and an initial equity investment of $75 million upon the closing of the transaction. It will also pay an additional $32 million equity contribution at the end of one year of closing the transaction.
Moreover, Noden expects to obtain debt financing with regard to the equity investment. PDL BioPharma may contribute additional amounts of equity depending upon the amount of debt obtained by Noden, and requirement for specified milestone payments or other purposes.
PDL BioPharma's investment will eventually reach 88% equity interest in Noden. The company will consolidate Noden's financial statements into its own, which will be immediately accretive to earnings.
We remind investors that Noden Pharma had executed a purchase agreement with Novartis AG (NVS - Free Report) to acquire rights to Tekturna and Tekturna HCT for the treatment of hypertension. Tekturna and Tekturna HCT are marketed in ex-U.S. countries as Rasilez and Rasilez HCT, respectively.
We note that the active ingredient of Tekturna and Tekturna HCT, aliskiren, is indicated for the treatment of hypertension. In 2015, Tekturna and Tekturna HCT generated revenues of $154 million.
PDL BioPharma currently carries a Zacks Rank #4 (Sell). A couple of better-ranked stocks in the health care sector are Bristol-Myers Squibb Company (BMY - Free Report) and Pfizer Inc. (PFE - Free Report) , both sporting a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>